Clinical and Translational Oncology

, Volume 15, Issue 9, pp 725–731 | Cite as

Management of malignant insulinoma

  • J. C. Ferrer-García
  • V. Iranzo González-CruzEmail author
  • S. Navas-DeSolís
  • M. Civera-Andrés
  • C. Morillas-Ariño
  • Á. Merchante-Alfaro
  • C. Caballero-Díaz
  • C. Sánchez-Juan
  • C. Camps Herrero
Research Article



Malignant insulinoma is an infrequent functional endocrine tumor of the pancreas. Adequate therapy is a demanding challenge for oncologists and endocrinologists.


To evaluate the results of multidisciplinary management of malignant insulinoma.

Materials and methods

Retrospective review of patients with malignant insulinoma treated from 1995 to 2011.


Seven patients with malignant insulinoma were included: four males and three females; median age was 61.8 years (range 37–78). Six tumors were sporadic and one was diagnosed in a patient with a type 1 multiple endocrine neoplasia (MEN-1). Surgery was performed in six cases and one patient was considered unresectable. Hypoglycemias persisted in all cases and somatostatin analogs, glucocorticoids and diazoxide were used. Two patients received everolimus. Other techniques were chemoembolization and internal radiation therapy with yttrium-90. Successful liver transplant was done in the patient with MEN-1.


Hypoglycemia management is complex and requires multiple therapies. Further evaluations will be necessary to determine the best treatment.


Insulinoma Neuroendocrine pancreatic tumor Hypoglycemia Islet cell tumors 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Service FJ, McMahon MM, O’Brien PC, Ballard DJ (1991) Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66:711–719PubMedCrossRefGoogle Scholar
  2. 2.
    Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN (2010) Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int. 9:234–241PubMedGoogle Scholar
  3. 3.
    Jensen RT (2006) Pancreatic neuroendocrine tumors: overview of recent advances and diagnosis. J Gastrointest Surg. 10:324–326PubMedCrossRefGoogle Scholar
  4. 4.
    Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR et al (2008) Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 247:165–172PubMedCrossRefGoogle Scholar
  5. 5.
    Alexakis N, Neoptolemos JP (2008) Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 22:183–205PubMedCrossRefGoogle Scholar
  6. 6.
    Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P (2005) Malignant insulinoma: spectrum of unusual clinical features. Cancer 104:264–272PubMedCrossRefGoogle Scholar
  7. 7.
    Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 132:976–982PubMedCrossRefGoogle Scholar
  8. 8.
    Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73:640–641PubMedCrossRefGoogle Scholar
  9. 9.
    Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG (2010) Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 162:1001–1008PubMedCrossRefGoogle Scholar
  10. 10.
    Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J (2003) Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 88:5353–5360PubMedCrossRefGoogle Scholar
  11. 11.
    de Sá S, Corrêa-Giannella ML, Machado MC, de Souza J, Pereira M, Patzina R, Siqueira S, Machado M, Giannella-Neto D (2006) Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer 13:69–78PubMedCrossRefGoogle Scholar
  12. 12.
    Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D (2011) Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing’s syndrome. Horm Metab Res 43:287–291PubMedCrossRefGoogle Scholar
  13. 13.
    Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Pasireotide Acromegaly Study Group (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95:2781–2789PubMedCrossRefGoogle Scholar
  14. 14.
    Novotny J, Janku F, Mares P, Petruzelka L (2005) Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer 13:760–762PubMedCrossRefGoogle Scholar
  15. 15.
    Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311–4318PubMedCrossRefGoogle Scholar
  16. 16.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K (2011) RAD001 in advanced neuroendocrine tumors, THIRD TRial (RADIANT-3) Study Group. N Engl J Med 364:514–523PubMedCrossRefGoogle Scholar
  17. 17.
    Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360:195–197PubMedCrossRefGoogle Scholar
  18. 18.
    Starke A, Saddig C, Mansfeld L, Koester R, Tschahargane C, Czygan P, Goretzki P (2005) Malignant metastatic insulinoma-postoperative treatment and follow-up. World J Surg 29:789–793PubMedCrossRefGoogle Scholar
  19. 19.
    Chandra P, Yarandi SS, Khazai N, Jacobs S, Umpierrez GE (2010) Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci 340:414–417PubMedCrossRefGoogle Scholar
  20. 20.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP et al (2005) Radiolabeled somatostatin analog 177-Lu-DOTA Tyr octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762PubMedCrossRefGoogle Scholar
  21. 21.
    Bégu-Le Corroller A, Valéro R, Moutardier V, Henry JF, Le Treut YP, Gueydan M, De Micco C, Sierra M, Conte-Devolx B, Oliver C, Raccah D, Favre R, Digue L, Heim M, Seitz JF, Delpero JR, Vialettes B (2008) Aggressive multimodal therapy of sporadic malignant insulinoma can improve survival: a retrospective 35-year study of 12 patients. Diabetes Metab 34:343–348PubMedCrossRefGoogle Scholar
  22. 22.
    Maiza JC, Vezzosi D, Grunenwald S, Otal P, Guimbaud R, Bennet A, Caron P (2011) Treatment with somatostatin analogues and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas. J Endocrinol Invest 34:253–258Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • J. C. Ferrer-García
    • 1
  • V. Iranzo González-Cruz
    • 2
    Email author
  • S. Navas-DeSolís
    • 3
  • M. Civera-Andrés
    • 4
  • C. Morillas-Ariño
    • 5
  • Á. Merchante-Alfaro
    • 1
  • C. Caballero-Díaz
    • 2
  • C. Sánchez-Juan
    • 1
  • C. Camps Herrero
    • 2
  1. 1.Department of Endocrinology and NutritionConsorcio Hospital General Universitario de ValenciaValenciaSpain
  2. 2.Department of OncologyConsorcio Hospital General Universitario de ValenciaValenciaSpain
  3. 3.Department of Endocrinology and NutritionHospital Universitario La FeValenciaSpain
  4. 4.Department of Endocrinology and NutritionHospital Clínico UniversitarioValenciaSpain
  5. 5.Department of Endocrinology and NutritionHospital Universitario Doctor PesetValenciaSpain

Personalised recommendations